Clinical trial
A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer, Gastric/Esophageal Cancer, and Relapsed/Refractory Hematologic Malignancies
NCT05400122 is registered in ClinicalTrials.gov with David Wald as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer, Gastric/Esophageal Cancer, and Relapsed/Refractory Hematologic Malignancies
- Lead sponsor
- David Wald
- Phase
- Phase 1
- Overall status
- Suspended
- Start date
- September 9, 2022
- Completion date
- June 1, 2027
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancer, esophageal cancer, esophagus cancer, gastric cancer, gastric cancer, metastatic, hematologic malignancy, hodgkin lymphoma, metastatic esophageal cancer, myelodysplastic syndromes, myeloproliferative syndrome, non hodgkin lymphoma, plasma cell myeloma, rectum cancer, unresectable esophageal cancer